Compare AbbVie Inc (ABBV) vs Carvana Co (CVNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Carvana Co — how do they compare? AbbVie Inc trades at $253.45 (market cap $449.91B), while Carvana Co trades at $65.91 (market cap $48.34B). The key difference: AbbVie Inc is far larger — about 9.3× Carvana Co's market cap, and AbbVie Inc pays a 2.72% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| ABBV | CVNA | |
|---|---|---|
Market Cap | $449.91B | $48.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $95.69 |
52-Week Low | $184.85 | $56.27 |
Enterprise Value | $513.38B | $50.99B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Carvana (CVNA) trades at $67.47, down 1.63% on the day, with a bullish technical signal and strong fundamental growth. Revenue surged to $20.32B in 2025, with net income reaching $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and expansion news includes same-day delivery in Milwaukee.
The outlook is positive with analyst consensus at Buy and a $93.92 price target, but risks include high debt levels and competitive pressures. Upside potential exists from operational efficiency and market expansion, yet volatility from used-car market softness remains a concern for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
